JANX Q2 2022 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+390.7% YoY

Gross Profit

-$12M-495.6% margin

Operating Income

-$17M-729.9% margin

Net Income

-$17M-714.1% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+48.8%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$385M

Total Liabilities

$42M

Stockholders' Equity

$344M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$482,000	+390.7%
Gross Profit	-$12M	-$4M	-175.5%
Operating Income	-$17M	-$6M	-176.1%
Net Income	-$17M	-$6M	-172.1%